Sample size calculations are important for planning drug trials and require
anticipation of the proportion of potential patients finally recruited. Be
cause most recent drug studies fur dementia have similar requirements, it c
ould be helpful to analyze the recruitment rare of recent studies. Records
of demented patients candidates for drug trials fur treatment of dementia o
f the Alzheimer type in 1994-1995 were analyzed for recruitment rate and re
asons for nonrecruitment. From 279 patients with dementia of the Alzheimer
type, only 13% were finally included in drug studies. The main reasons for
non-enrollment included (1) cognitive test scores out of range for study in
clusion criteria (Mini-Mental State Examination [MMSE] <12 [30%], MMSE >24
[5%]), (2) behavioral disturbances (25%), and (3) concomitant diseases (12%
). Consent was refused in 8% of those to whom the experimental drug was off
ered. This low rate of enrollment, 13% of potential candidates, does not in
clude postrecruitment drop-out cases, nor the availability of nonexperiment
al therapy for DAT. Further, the high selection may limit the generalizabil
ity of the results of such studies.